Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder [PDF]
Neurology and TherapyIntroduction Anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) is a complement-mediated autoimmune disease in which unpredictable and relapsing attacks on the central nervous system cause irreversible and ...
Stacey L. Clardy +10 more
doaj +2 more sources
Non-capsulated Neisseria meningitidis sepsis in a paroxysmal nocturnal hemoglobinuria patient treated with ravulizumab: case report and review of the literature [PDF]
Frontiers in Immunology, 2023 Paroxysmal nocturnal haemoglobinuria (PNH) is a rare acquired haematopoietic stem cell disease characterized by complement-mediated intravascular hemolysis, thrombosis, and bone marrow failure. Eculizumab and ravulizumab are anti-C5 monoclonal antibodies
Nicole Galli +11 more
doaj +3 more sources
Eculizumab and ravulizumab clinical trial and real-world pharmacovigilance of meningococcal infections across indications. [PDF]
PLoS ONEIntroductionComplement component 5 inhibitor therapies (C5ITs) for rare hematological, renal, and neurological diseases are associated with increased meningococcal infection risk. Robust risk mitigation measures include vaccination, drug safety programs,
Cynthia Carrillo Infante +1 more
doaj +2 more sources
Ravulizumab in NMOSD with associated interstitial pneumonitis in a 59-year-old female patient: a case report [PDF]
Frontiers in ImmunologyIntroductionNeuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system often associated with aquaporin-4-immunoglobulin-G (AQP4-IgG), which activate the complement system, and it can lead to progressive ...
Andrea Neundorf, Ralf Dittrich
doaj +2 more sources
Real-World Prevalence and Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors in the US: A Retrospective Claims Database Analysis [PDF]
Journal of Health Economics and Outcomes Research# Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder with C5 inhibitors (C5i), eculizumab and ravulizumab, being part of current treatment options.
Srinivas K Tantravahi +9 more
doaj +2 more sources
Long-term effectiveness and safety of ravulizumab in paroxysmal nocturnal hemoglobinuria: a plain language summary [PDF]
Journal of Comparative Effectiveness ResearchWhat is this summary about? Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease where red blood cells break apart because they lack certain protective proteins.
Celso Arrais +2 more
doaj +2 more sources
Oral Corticosteroid and Nonsteroidal Immunosuppressant Therapy Use in Patients with Myasthenia Gravis Receiving Ravulizumab, Eculizumab, or Efgartigimod in the USA [PDF]
Neurology and TherapyIntroduction Oral corticosteroids (OCSs) and nonsteroidal immunosuppressant therapies (NSISTs) remain widely used for the clinical management of patients with generalized myasthenia gravis (gMG), despite well-documented risks.
Francesco Saccà +4 more
doaj +2 more sources
Disease Activity After Switching From Eculizumab to Ravulizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria: Real World Data From Denmark and Finland [PDF]
eJHaemIntroduction Ravulizumab replaced eculizumab as the preferred complement inhibitor for Paroxysmal Nocturnal Haemoglobinuria (PNH) in Denmark and Finland after 2020. Data on real‐world disease activity after switching are limited.
Anders Rønneholt‐Frederiksen +8 more
doaj +2 more sources
Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network [PDF]
Frontiers in ImmunologyObjectiveTo integrate pharmacovigilance and network pharmacology methods for a comprehensive analysis of the potential adverse reactions of complement C5 inhibitors (eculizumab, ravulizumab, zilucoplan) and neonatal Fc receptor (FcRn) inhibitors ...
Luqiong Wang +5 more
doaj +2 more sources
Comparative Efficacy of Complement Inhibitors in Complement Inhibitor-Naïve PNH: A Systematic Review With Supportive Exploratory Network Meta-Analysis of Randomized Trials. [PDF]
EJHaemABSTRACT Introduction Paroxysmal nocturnal haemoglobinuria (PNH) is an uncommon, life‐threatening disease, caused by intravascular haemolysis by the complement system. In this review, we aim to compare the efficacy of the available agents across patient‐centred outcomes in complement inhibitor‐naive patients.
Ishaque R +7 more
europepmc +2 more sources